Adagene Inc. released updated Phase 1b/2 clinical trial data for ADG126, a novel anti-CTLA-4 antibody, combined with pembrolizumab in...

Candel Therapeutics announced positive Phase 3 trial results for aglatimagene besadenovec (CAN-2409) combined with valacyclovir in patients with intermediate-to-high-risk...

Belite Bio has received Breakthrough Therapy Designation from the FDA for Tinlarebant, its treatment for Stargardt disease (STGD1), based...

Soleno Therapeutics announced positive data from its clinical development program for VYKAT XR (diazoxide choline) extended-release tablets, a treatment...

A patient with advanced cutaneous squamous cell carcinoma (CSCC) experienced complete tumor remission after 12 weeks in a clinical...

Oruka Therapeutics has started dosing healthy volunteers in a Phase 1 clinical trial for ORKA-002, a novel subcutaneous monoclonal...

Marker Therapeutics announced preliminary findings from its Phase 1 APOLLO study, showing that lymphodepletion, a pre-conditioning regimen, improves the...

Cingulate Inc. announced positive efficacy results from a Phase 3 clinical trial of CTx-1301, its dexmethylphenidate-based ADHD treatment, in...

SPR announced positive results from its MONARCH study, which investigated the use of its SPRINT PNS System for treating...

Silo Pharma (Nasdaq: SILO) partnered with Resyca BV to conduct a drug-device study for their lead asset, SPC-15, an...